Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies
- 30 August 2022
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (22) , 4107-4113
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) refers to the expansion of cells of hematopoietic lineage that carry acquired somatic alterations associated with hematologic malignancies. The most commonly altered genes giving rise to CHIP are DNMT3A, TET2, and ASXL1. However, advanced sequencing technologies have resulted in highly sensitive detection of clonal hematopoiesis beyond these known driver genes. In practice, CHIP is commonly identified as an incidental finding in liquid and tissue biopsies of patients with solid tumors. CHIP can have broad clinical consequences, given its association with hematologic malignancies and nonmalignant diseases. CHIP can also interfere with next-generation DNA sequencing results, so clinicians should pay careful attention when these results are being used to guide therapy. Future research is needed to determine how solid tumor malignancies and their treatments alter the progression of CHIP, and in turn, how CHIP might be used to improve treatment selection and outcomes for patients with solid tumors.Keywords
Funding Information
- National Cancer Institute (P30 CA006973)
- V Foundation for Cancer Research
- Prostate Cancer Foundation
This publication has 80 references indexed in Scilit:
- Causes of death among cancer patientsAnnals of Oncology, 2016
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemiasAmerican Journal of Hematology, 2015
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA SequenceNew England Journal of Medicine, 2014
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Hematopoiesis: A Human PerspectiveCell Stem Cell, 2012
- Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012)Breast Cancer Research and Treatment, 2009
- The Hallmarks of CancerCell, 2000